Answers are grounded in this paper and cite their sources.
The high acquisition rate of HIV infection among women in the United States is concerning. Despite the FDA approving the first pre-exposure prophylaxis (PrEP) drug in 2012, PrEP utilization remains significantly lower among women. This literature review aims to analyze the current body of research concerning HIV PrEP usage among women in the US.
No takes yet. Share an insight, caveat, or question.
Mathurin et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: